ATE387909T1 - Verfahren und zusammensetzungen zur behandlung von neoplastischen erkrankungen mittels chemotherapie und strahlungssensibilisatoren - Google Patents

Verfahren und zusammensetzungen zur behandlung von neoplastischen erkrankungen mittels chemotherapie und strahlungssensibilisatoren

Info

Publication number
ATE387909T1
ATE387909T1 AT01948255T AT01948255T ATE387909T1 AT E387909 T1 ATE387909 T1 AT E387909T1 AT 01948255 T AT01948255 T AT 01948255T AT 01948255 T AT01948255 T AT 01948255T AT E387909 T1 ATE387909 T1 AT E387909T1
Authority
AT
Austria
Prior art keywords
methods
kiaa0175
compositions
neoplastic diseases
chemotherapy
Prior art date
Application number
AT01948255T
Other languages
English (en)
Inventor
Bin Wu
Todd Seeley
Lewis Williams
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of ATE387909T1 publication Critical patent/ATE387909T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01037—Protein kinase (2.7.1.37)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
AT01948255T 2000-05-31 2001-05-30 Verfahren und zusammensetzungen zur behandlung von neoplastischen erkrankungen mittels chemotherapie und strahlungssensibilisatoren ATE387909T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20843500P 2000-05-31 2000-05-31

Publications (1)

Publication Number Publication Date
ATE387909T1 true ATE387909T1 (de) 2008-03-15

Family

ID=22774595

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01948255T ATE387909T1 (de) 2000-05-31 2001-05-30 Verfahren und zusammensetzungen zur behandlung von neoplastischen erkrankungen mittels chemotherapie und strahlungssensibilisatoren

Country Status (10)

Country Link
US (2) US6974867B2 (de)
EP (1) EP1292289B1 (de)
JP (1) JP2003534786A (de)
AT (1) ATE387909T1 (de)
AU (1) AU2001269726A1 (de)
CA (1) CA2410516A1 (de)
DE (1) DE60133104T2 (de)
ES (1) ES2299493T3 (de)
PT (1) PT1292289E (de)
WO (1) WO2001091739A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120045390A1 (en) * 2002-09-11 2012-02-23 Genentech, Inc. Composition and Methods for the Diagnosis and Treatment of Tumor
US7879545B2 (en) * 2003-11-05 2011-02-01 H. Lee Moffitt Cancer Center And Research Institute, Inc. Identification of novel targets for radio sensitization using a genomic-based radiation sensitivity classifier
JP5028601B2 (ja) * 2004-08-10 2012-09-19 オンコセラピー・サイエンス株式会社 乳癌に関連する遺伝子およびポリペプチド
US20090163406A1 (en) * 2004-09-30 2009-06-25 The Regents Of The University Of California Compositions and methods for diagnosing and treating brain cancer and identifying neural stem cells
US20090076734A1 (en) * 2007-03-22 2009-03-19 Torres-Roca Javier F Gene Signature for the Prediction of Radiation Therapy Response
US20080234946A1 (en) 2007-03-22 2008-09-25 University Of South Florida Predictive radiosensitivity network model
CA2699376C (en) * 2007-09-14 2018-10-23 University Of South Florida Gene signature for the prediction of radiation therapy response
TWI466680B (zh) 2008-08-01 2015-01-01 Oncotherapy Science Inc Ｍｅｌｋ抗原決定位胜肽及含此胜肽的疫苗
TWI485245B (zh) 2010-01-25 2015-05-21 Oncotherapy Science Inc 經修飾之ｍｅｌｋ胜肽及含此胜肽之疫苗
US8673308B2 (en) * 2011-02-23 2014-03-18 Als Therapy Development Institute Targeting of CD8+ T-lymphocytes to treat neurodegenerative diseases
WO2014130955A1 (en) 2013-02-25 2014-08-28 Sangamo Biosciences, Inc. Methods and compositions for enhancing nuclease-mediated gene disruption
CN113444747A (zh) 2014-11-21 2021-09-28 瑞泽恩制药公司 使用成对向导rna进行靶向遗传修饰的方法和组合物
EP3457840B1 (de) 2016-05-20 2024-04-10 Regeneron Pharmaceuticals, Inc. Verfahren zur durchbrechung einer immunologischen toleranz unter verwendung mehrerer guide-rnas

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5700637A (en) * 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
CA2264012C (en) 1996-08-13 2011-04-26 Chiron Corporation Compositions and methods for polynucleotide delivery
US6197332B1 (en) 1997-08-13 2001-03-06 Chiron Corporation Lipid-conjugated polyamide compounds and related compositions and methods thereof
US6087485A (en) * 1998-01-21 2000-07-11 Axys Pharmaceuticals, Inc. Asthma related genes
WO1999065928A2 (en) * 1998-06-19 1999-12-23 Genzyme Corporation Polynucleotide population isolated from non-metastatic and metastatic breast tumor tissues
DE60038220T2 (de) 1999-08-27 2009-03-12 Novartis Vaccines and Diagnostics, Inc., Emeryville Chimerische antisense-oligonukleotide und zelltransfektions-zusammensetzungen davon

Also Published As

Publication number Publication date
EP1292289B1 (de) 2008-03-05
DE60133104T2 (de) 2009-03-12
EP1292289A2 (de) 2003-03-19
AU2001269726A1 (en) 2001-12-11
CA2410516A1 (en) 2001-12-06
WO2001091739A2 (en) 2001-12-06
DE60133104D1 (de) 2008-04-17
US20050282766A1 (en) 2005-12-22
WO2001091739A3 (en) 2003-01-16
PT1292289E (pt) 2008-04-23
ES2299493T3 (es) 2008-06-01
JP2003534786A (ja) 2003-11-25
US6974867B2 (en) 2005-12-13
US20020049180A1 (en) 2002-04-25

Similar Documents

Publication Publication Date Title
ATE387909T1 (de) Verfahren und zusammensetzungen zur behandlung von neoplastischen erkrankungen mittels chemotherapie und strahlungssensibilisatoren
Karlitepe et al. New approaches for cancer immunotherapy
SG170080A1 (en) Human monoclonal antibodies to o8e
ATE459648T1 (de) Fusionsprotein von antikörper l19 gegen fibronectin ed-b und interleukin 12
TW200513532A (en) VEGF traps and therapeutic uses thereof
ATE545699T1 (de) Modifizierte, rekombinante vacciniaviren und deren verwendungen
ATE294591T1 (de) Verwendung von trifunktionellen bispezifischen und trispezifischen antikörpern zur behandlung von malignem aszites
RU94045281A (ru) Иммуноконъюгаты, способ получения иммуноконъюгата, фармацевтическая композиция, применение иммуноконъюгата
DK0784683T3 (da) TIE-2-ligander, fremgangsmåder til dannelse af disse og anvendelser deraf
SG163554A1 (en) Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
ATE517638T1 (de) Verfahren und zubereitungen zum verabreichen von therapeutischen und diagnostischen mitteln
MX2022000652A (es) Anticuerpos contra claudina 18 y metodos de tratamiento del cancer.
EP3530736A3 (de) Humane monoklonale antikörper für den programmierten tod 1 (pd-1) und verfahren zur behandlung von krebs mit pd-1-antikörpern allein oder in kombination mit anderen immunotherapeutika
BR0315666A (pt) Dna de a34 e a33 do tipo 3, proteìnas, seus anticorpos e métodos de tratamento usando os mesmos
HK1091216A1 (en) Growth factor complexes and modulation of cell migration and growth
Kemper et al. Targeting colorectal cancer stem cells with inducible caspase-9
DE69834824D1 (de) Nukleinsäure, welche einen von lektin abstammenden faktor zur präservierung von progenitorzellen kodiert
NO993943D0 (no) Kombinert tumorsuppressorgenterapi og kjemoterapi ved behandling av neoplasmer
Yin et al. Intranasal delivery of immunotherapeutic nanoformulations for treatment of glioma through in situ activation of immune response
MX2021011330A (es) Anticuerpos de claudina-6 y conjugados de fármacos.
ATE287722T1 (de) Mittel zur behandlung maligner erkrankungen unter verwendung des proteins yb-1
Ye et al. Suppression of CD26 inhibits growth and metastasis of pancreatic cancer
DE60109359D1 (de) Verwendung von anti-ferritin antikörper bei der behandlung von bestimmten krebsarten
EA200700346A1 (ru) Бактериофаг- и профаг-специфические протеины в генной терапии рака
MX2021008453A (es) Formulaciones de anticuerpos que se unen a cd137 humano y usos de los mismos.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1292289

Country of ref document: EP

REN Ceased due to non-payment of the annual fee